Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22229629 | 1.00 | ROCK2 (0.38) | ROCK2KDM4ENPC1RAB9ADPP4 | |
| SCHEMBL28443783 | 0.91 | KDM4E (0.42) | ROCK2KDM4ENPC1RAB9AGRM4 | |
| SCHEMBL22229646 | 0.89 | ROCK2 (0.39) | ROCK2KDM4ENPC1RAB9ADPP4 | |
| SCHEMBL30189598 | 0.89 | ROCK2 (0.39) | ROCK2KDM4ENPC1RAB9ADPP4 | |
| SCHEMBL22229605 | 0.89 | GRM4 (0.39) | ROCK2GRM4HRH4 | |
| SCHEMBL22229617 | 0.89 | GRM4 (0.31) | GRM4HRH4 | |
| SCHEMBL30189725 | 0.89 | GRM4 (0.39) | ROCK2GRM4HRH4 | |
| SCHEMBL30189449 | 0.89 | GRM4 (0.31) | GRM4HRH4 | |
| SCHEMBL22229650 | 0.86 | ROCK2 (0.43) | ROCK2 | |
| SCHEMBL22229580 | 0.86 | ROCK2 (0.40) | ROCK2GRM4HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542256-B2 | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors | ANGION BIOMEDICA CORP. (US) | 2023-01-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542256-B2 | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885KDM4E 2076/4885NPC1 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.